Indication
Treatment of symptomatic obstructive hypertrophic cardiomyopathy.
Official EMA Resources
View on EMA (ema.europa.eu)AI Drug & Interaction Analysis
Loading your page…
Loading your page…
Cardiomyopathy, Hypertrophic
Marketing Authorisation Holder: Bristol-Myers Squibb Pharma EEIG
EMA Authorisation: 26/06/2023
INN: mavacamten
AI Drug & Interaction Analysis
Free account required
Ask Osler about Camzyos: drug interactions and guideline evidence, with every claim numbered to its source. For reference and learning, not treatment advice.
Medical disclaimer: This information is intended for qualified healthcare professionals. Always verify with the official EMA Summary of Product Characteristics (SmPC) before clinical use.